Simini Technologies Inc.
$34,263.60 CAD
≈ 5 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2018-2019
- Agreement period
- October 17, 2018 – November 30, 2019
- Reference
- nrc-cnrc:172-2018-2019-Q3-914972
Published purpose
SMN-023 is new a topical therapy for canine atopic dermatitis. This study is designed to show proof of concept that SMN-023 can be the first pharmaceutical approved as a maintenance therapy to delay the onset of atopic dermatitis flares in dogs.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported August 3, 2026 from open.canada.ca Grants & Contributions